Altimmune’s Pemvidutide Garners Mixed Reviews Following Phase II Obesity Data

Stock Down By 55%

The US firm’s GLP-1/glucagon receptor agonist improved weight loss in a Phase II interim analysis, but concerns about drug safety and discontinuation have left investors cynical, even as analysts remain cautiously upbeat.  

Weighing scales with measuring tape, fruits and dumbbells
Pemvidutide Was Combined With Diet And Exercise Measures • Source: Shutterstock

Altimmune Inc.’s pemvidutide has shown promising efficacy in a Phase II non-diabetic obesity trial but investors have been spooked by the rate of treatment discontinuations associated with adverse events, although analysts agreed safety concerns were overblown.

Pemvidutide is a GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol related steatohepatitis (NASH). Its...

More from Clinical Trials

More from R&D